Skip to main content
. 2022 Dec 8;192(5):2179–2187. doi: 10.1007/s11845-022-03235-z

Table 2.

LT4 formulations preferred by respondents in different clinical scenarios

“I expect no major changes
with the different
formulations”
n (%)
Liquid
solution
n (%)
Tablets
n (%)
Soft-gel
capsules
n (%)
Tablets form another manufacturer
n (%)
Interfering drugs may influence the stability of therapy. Which LT4 preparation is in your experience less likely to be subject to variable absorption? 23(58.9%) 4(10.3%) 12 (30.8%) 0 (0%) 0 (0%)
Which of the following preparations of LT4 would you prescribe in case of a first diagnosis of hypothyroidism, when the patient self-reports intolerance to various foods raising the possibility of celiac disease, malabsorption, lactose intolerance or intolerance to excipients? 9 (23.1%) 2 (5.1%) 28 (71.8%) 0 (0%) 0 (0%)
Which of the following preparations of LT4 would you prescribe for a patient established on generic LT4 who has unexplained poor biochemical control of hypothyroidism? 23(58.9%) 1(2.6%) 0 (0%) 1(2.6%) 14(35.9%)
Which of the following preparations of LT4 would you prescribe for a patient with poor biochemical control who is unable (due to busy lifestyle) to take LT4 fasting and separate from food/drink? 19 (48.7%) 2 (5.1%) 16(41%) 2 (5.1%) 0 (0%)
Which of the following preparations of LT4 would you prescribe for a patient established on generic T4 who has good biochemical control of hypothyroidism but continues to have symptoms? 31 (79.5%) 0 (0%) 0 (0%) 1(2.6%) 7 (17.9%)